齐拉西酮与利培酮治疗女性精神分裂症临床对照研究

目的比较齐拉西酮与利培酮治疗女性精神分裂症患者的疗效及副反应。方法将符合入组标准的100例女性精神分裂症患者随机分为齐拉西酮组与利培酮组各50例进行为期8周的治疗。采用阳性与阴性症状量表（PNASS）评定疗效、副反应量表（TESS）评定副反应。并采用放射免疫法于治疗前和治疗后2、4、8周末分别测定血清催乳素（PRL）水平。结果8周末PANSS的减分率齐拉西酮组与利培酮组分别为70．01％和69．59％。PANSS总分及阳性症状分、阴性症状分、一般病理分两组治疗前后均有显著性差异（P〈0．01），但两组之间无明显差异。齐拉西酮组TESS评分为3．55±2．46，利培酮组为3．72±2．57，不良反应均轻微。8周末血清PRL水平，齐拉西酮组为13．9±12．5ug／L，与治疗前比较差别无显著性意义（P〉0．05）；利培酮组为121．8±76．4ug／L，与治疗前比较差别有显著性（P〈0．01）。两组比较差别有显著性（P〈0．01）。结论齐拉西酮临床疗效好，不良反应轻微，对女性患者血清PRL水平影响小，是一种较为理想的抗精神病药。

Comparative Study of Ziprasidone Hydrochloride and Risperdal in Treatment of Female Schizophrenia

Objective To evaluate the efficacy and safety of Ziprasidone Hydrochloride and Risperdal in treatment of female schizophrenia. Methods A total of 100 female patients with schizophrenies were randomly divided into Ziprasidone Hydrochloride group （n= 50） and Risperdal（n = 50）group. Antipsychotic efficacy was assessed using the Positive and Negative symptom scale （PANSS） ,Antipsychotic tolerability was assessed by Treatment Emergent Symptom Scale （TESS）. The serum prolactin level was measured respectively at pre-treatment and the 2nd, 4th, 8th week. Results As compared withthe baseline scores, PANSS reduction was （7 0.01 ± 19.28）% in Ziprasidone Hydrochloride group, and （69.59 ± 20. 92） % in Risperdal group. The PANSS scores as well as positive subscale scores and negative subscale scores decreased significantly after 8 weeks＇ treatment（P〈0.01）,but had no significant difference between the 2 grohps. No serious adverse events were found during the treatment. The PRL was（13.9± 12. 5）μg/L in Ziprasidone Hydrochloride group,compared （121.8 ± 76.4）μg/L in Risperdal group. There was significant difference between the 2 groups（P〈0.01）. There was no obvious PRL difference between the base line and 8th week end in Ziprasidone Hydrochloride group. Conclusion Ziprasidone Hydrochloride has reliable effectiveness with fewer side effects, and may be a suitable therapy in the treatment of schizophrenia.